Articles From: EOPN INVESTOR ALERT: The Law Offices of Vincent Wong Launches an Investigation of the Board of Directors of E2open, Inc. In Connection With the Fairness of the Sale of the Company to Insight Venture Partners to Epizyme Appoints Andrew Singer as Chief Financial Officer


2015/2/11
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of E2open, Inc. (NASDAQ GM:EOPN) (“E2open”) in connection with the sale of the Company to Insight Venture Partners.
Sign-up for EOPN INVESTOR ALERT: The Law Offices of Vincent Wong Launches an Investigation of the Board of Directors of E2open, Inc. In Connection With the Fairness of the Sale of the Company to Insight Venture Partners investment picks
2015/2/13
HOUSTON , Feb.
Sign-up for EP Energy to Provide 2014 Results and 2015 Outlook investment picks
2014/12/9
VANCOUVER , Dec.
Sign-up for EPA Issues Draft Underground Injection Control Permit to Florence Copper investment picks
2015/3/2
http://www.marketwire.com/library/MwGo/2015/3/2/11G034621/EPIC_Corporation-949224062297.jpg AUSTIN, TX--(Marketwired - March 02, 2015) - EPIC Corporation Inc. (OTC PINK: EPOR) and Ronald Tucker its CEO announced "EPIC's Board of Directors declares the eighth consecutive quarterly stock dividend on its Series A 5% Convertible Preferred Stock to preferred shareholders of record on March 24, 2014, which will be paid March 31, 2014.
Sign-up for EPIC Declares Its Eighth Consecutive Quarterly Preferred Stock Dividend investment picks
2014/12/22
http://www.marketwire.com/library/MwGo/2014/12/22/11G029088/EPIC_Corporation-949224062297.jpg AUSTIN, TX--(Marketwired - December 22, 2014) - EPIC Corporation Inc. (OTC PINK: EPOR) and Ronald Tucker, its CEO, announced, "EPIC's Board of Directors has authorized an offer to exchange shares of its Series A 5% Convertible Preferred Stock for common stock.
Sign-up for EPIC Offers a Second Exchange of Its Series A Preferred Stock in Place of Its Announced Dividend Policy investment picks
2015/1/12
http://www.marketwire.com/library/MwGo/2015/1/12/11G030114/EPIC_Corporation-949224062297.jpg AUSTIN, TX--(Marketwired - January 12, 2015) - EPIC Corporation Inc. (OTC PINK: EPOR) and Ronald Tucker it CEO announced "EPIC's Board of Directors has authorized a series of quarterly exchange offerings for its common shareholders in street name to exchange common shares for preferred shares.
Sign-up for Epic Offers Common Shareholders Three Methods to Receive a Return on Investment, One Method Could Provide a 500% to 888% Annualized Rate of Return investment picks
2015/1/22
KANSAS CITY, Kan., Jan.
Sign-up for Epiq Systems and Contoural Announce Global Partnership to Deliver Information Governance Solutions investment picks
2015/1/12
KANSAS CITY, Kan., Jan.
Sign-up for Epiq Systems Appoints President and Chief Operating Officer Brad D. Scott to Board of Directors investment picks
2015/1/7
KANSAS CITY, Kan., Jan.
Sign-up for Epiq Systems Names Andrew Shimek as Managing Director, Global eDiscovery Solutions investment picks
2014/12/15
KANSAS CITY, Kan., Dec.
Sign-up for Epiq Systems Names Chris Jutkiewicz Senior Vice President and Chief Technology Officer to Strengthen Global Technology Footprint investment picks
2015/1/12
KANSAS CITY, Kan., Jan.
Sign-up for Epiq Systems to Host Webcast on Data Security on January 15, 2015 investment picks
2015/2/10
KANSAS CITY, Kan., Feb.
Sign-up for Epiq Systems to Report 2014 Results and Host Call on Monday, March 2nd at 4:30 pm ET investment picks
2015/1/26
EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS), a Boston-based biopharmaceutical company focused on the global development of biosimilar monoclonal antibodies, announced today that it has commenced an underwritten public offering of shares of its common stock.
Sign-up for EPIRUS Announces Proposed Public Offering of Common Stock investment picks
2015/2/5
EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, today announced that the Company is scheduled to present a corporate overview at the Leerink Global Healthcare Conference in New York City on Thursday, February 12, 2015 at 11:35 a.m. Eastern Time.
Sign-up for EPIRUS Biopharmaceuticals to Present at Leerink Global Healthcare Conference investment picks
2015/1/20
ADVISORY, Jan.
Sign-up for EPIRUS Biopharmaceuticals, Inc. (Nasdaq: EPRS) to Ring The Nasdaq Stock Market Closing Bell investment picks
2015/1/30
EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS), a Boston-based biopharmaceutical company focused on the global development of biosimilar monoclonal antibodies, announced today the pricing of an underwritten public offering of 9.6 million shares of its common stock, offered at a price to the public of $5.00 per share.
Sign-up for EPIRUS Prices $48 Million Public Offering of Common Stock investment picks
2015/2/12
http://www.ccnmatthews.com/logos/20080922-epistem200.jpg MANCHESTER, UNITED KINGDOM --
Sign-up for Epistem Announces the Successful Evaluation of New RNA-AMP(TM) (RNA-Amplification) Technology investment picks
2015/2/16
EPIX and DISH Network L.L.C. have reached a multi-year renewal agreement for continued carriage of EPIX to DISH customers.
Sign-up for EPIX and DISH Renew Carriage Agreement investment picks
2015/1/29
Premium entertainment network EPIX celebrates Golden Globe® winners and Academy Award® Nominees with an encore primetime marathon of Hollywood Sessions February 9 through February 13 at 8pm ET/PT, 7C , to coincide with the return of Oscar® ballots.
Sign-up for EPIX Celebrates Golden Globe® Winners and Academy Award® Nominees with Primetime Marathon of Hollywood Sessions investment picks
2015/1/21
Premium TV network EPIX announced today that its Original Documentary Deep Web , chronicling one of the most important and riveting digital crime sagas of the century -- the October 2013 arrest of Ross William Ulbricht --
Sign-up for EPIX Documentary Investigates the Arrest of Ross Ulbricht, the Alleged “Dread Pirate Roberts” -- Founder of Online Black Market Silk Road, in the Original Documentary “Deep Web” investment picks
2015/1/13
EPIX, the first premium entertainment network created to capitalize on the “TV Everywhere” era, today announced that it has named Jocelyn Diaz, former Vice President of Production at Walt Disney Studios, as Executive Vice President for Original Programming.
Sign-up for EPIX Names Jocelyn Diaz as Executive Vice President for Original Programming investment picks
2015/1/26
EPIX Presents Road To the NHL Stadium Series™ brought to you by Coors Light will make its U.S. Television Premiere on EPIX February 3 at 10pm ET/PT, 9C with four weekly episodes focused on the reigning Stanley Cup® Champion Los Angeles Kings and their division rivals, the San Jose Sharks, as they prepare for the 2015 Coors Light NHL Stadium Series™ at Levi’s® Stadium in Santa Clara, California on Saturday, February 21.
Sign-up for EPIX Presents Road To the NHL Stadium Series™ brought to you by Coors Light U.S. Television Premiere on February 3 at 10pm ET/PT, 9C investment picks
2015/2/10
Premium TV network EPIX announced today that stand-up’s biggest and most off-the-wall comics Jim Norton, Jim Breuer and Lisa Lampanelli will star in three new hour-long Original Comedy Events.
Sign-up for EPIX Takes a New Slate of Comedy Programming to the Stage Starring Some of Today’s Wittiest and Most Cutting-Edge Stand-Up Comics investment picks
2015/3/3
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers , announced today that updated data from the ongoing Phase 1 dose escalation study of EPZ-6438 (referred to as E7438 by Epizyme's partner Eisai) were presented by Vincent Ribrag, M.D., Institut Gustave Roussy at the 13 th International Congress on Targeted Anticancer Therapies in Paris, France.
Sign-up for Epizyme Announces Presentation of Data from Phase 1 Study of EZH2 Inhibitor EPZ-6438 (E7438) investment picks
2015/2/3
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced that Andrew Singer will join the Company as Chief Financial Officer on February 9th.
Sign-up for Epizyme Appoints Andrew Singer as Chief Financial Officer investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: EOPN INVESTOR ALERT: The Law Offices of Vincent Wong Launches an Investigation of the Board of Directors of E2open, Inc. In Connection With the Fairness of the Sale of the Company to Insight Venture Partners to Epizyme Appoints Andrew Singer as Chief Financial Officer
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent